Skip to main content
. 2019 Jun 12;3:PO.19.00014. doi: 10.1200/PO.19.00014

FIG 4.

FIG 4.

Concordance of gene amplification calls between Guardant360 and the Vancouver panel. (A) Absolute gene copy number (estimated with the Vancouver panel) of AR compared with six other genes. Copy numbers were estimated based on sequencing coverage log ratio and circulating tumor (ctDNA) fraction (described in Patients and Methods) and represent the average gene copy numbers in ctDNA-shedding cancer cells. Circle size represents the estimated ctDNA fraction of a sample. (B) Sequencing coverage log ratios of genes MET, BRAF, CDK6, PIK3CA, MYC, CCND1, and AR, quantified with the Vancouver panel in all 24 cfDNA samples. Bars highlighted in blue indicate that the gene was reported as amplified by Guardant360 in that sample. Numbers above bars indicate the average gene copy numbers in ctDNA-shedding cancer cells that would produce the observed coverage log ratio in the Vancouver panel data, correcting for presence of normal cfDNA (Patients and Methods). Chr, chromosome.